Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans

Individuals who rely on public health payers to access new medicines can access fewer innovative medicines and must wait longer in Canada compared to major markets around the world. New medicines/indications approved by Health Canada and reviewed for eligibility for reimbursement by the Common Drug...

Full description

Bibliographic Details
Main Authors: Sam Salek, Sarah Lussier Hoskyn, Jeffrey Roy Johns, Nicola Allen, Chander Sehgal
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Pharmacology
Subjects:
reimbursement
time to list
Canada
patient access to new medicines
CADTH
health technology assessment
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00196/full

Similar Items

Similar Items